Clinical Trial Update: Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the PET radioligand [18F]T807 (AV-1451) for imaging tau in Alzheimer's disease has completed. The trial provides initial quantitative d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F]T807 (T807 (AV-1451))

Snippet

Sponsor: Molecular NeuroImaging | Conditions: Alzheimer's Disease (AD) | Phase 1 | Status: COMPLETED